The V599E BRAF mutation is uncommon in biliary tract cancers.

摘要: Activating point mutations of the BRAF oncogene have been identified in several solid tumors, most commonly cutaneous melanomas and papillary carcinomas thyroid. A specific mutation--V599E--accounts for overwhelming majority these mutational events. We explored frequency V599E mutation biliary tract cancers. In all, 62 archival cancers, including 15 gallbladder extrahepatic, 10 intrahepatic cholangiocarcinomas from United States, 22 Chile were analyzed gene using three distinct methods: direct sequencing, a primer extension method (Mutector assay), highly sensitive quantitative Gap Ligase Chain Reaction. The common was not any cancer samples methods detection. somatic is absent at least two geographic populations (United States Chile) examined. Activation RAS/RAF/MAP kinase pathway cancers likely to be secondary oncogenic RAS mutations, or due nucleotide positions current study.